Search - tctmd.com

Displaying 141 - 153 of 153

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Boston Heart Reaches Milestone in Statin Intolerance Testing

September 08, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Daily News

Poor Responders to Statins at Risk for CAD Progression

March 11, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2016

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Boston Heart Reaches Milestone in Statin Intolerance Testing

FDA approves Repatha to treat certain patients with high cholesterol

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Poor Responders to Statins at Risk for CAD Progression

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content